Lutetium-177 PSMA radioligand therapy for advanced #ProstateCancer: Reviewing the pivotal #VISION and #TheraP trials. Michael Morris Memorial Sloan Kettering Cancer Center joins Dan George Duke Cancer in this discussion on UroToday > bit.ly/3OKLwn4

Congratulations marisa kollmeier! Well deserved!

Inspiration for the August cover art: First-in-human trial of #imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade #neuroendocrinetumours of the lung and prostate thelancet.com/journals/lanon… #NeuroendocrineTumors #SCLC

Online now at European Urology Oncology is exciting work by Jennifer Ma, MD Luke del Balzo Henry Walch, co-mentored with Ritesh Kotecha. The largest series of RCC BM genomics, identifying genomic biomarkers correlated with CNS outcome after SRS. Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Radiation Oncology doi.org/10.1016/j.euo.…

The FDA has approved a new drug that slows the growth of low-grade diffuse #gliomas with a certain gene mutation based on a clinical trial led by MSK's Dr. Ingo Mellinghoff. Learn more: bit.ly/4cf4o6l

Congrats to Muneeb Alam on well deserved #BCANTT24 travel fellowship award, no doubt he will make a big impact on the #bladdercancer field! UrologyMSK Rebecca Johnson YUO Society of Urologic Oncology David B. Solit, MD Bernie Bochner, MD Hikmat Al Ahmadie Gopa Iyer

Bladder Cancer Advocacy Network #BCANTT24 is all about putting the patients' voices at the center of all we do! #DianeQuale led a great, interactive session with pts who shared their inspiring stories! Eugene Pietzak Jonathan Rosenberg MD Max Kates Omar Mian Petros Grivas

#BCANTT24 A great overview by Thomas Flaig, chair of National Comprehensive Cancer Network (NCCN) #BladderCa guidelines on the process, adaptability, global implementation of the robust guidelines. ~50% use outside of US where many tx not even available/accessible. Andrea Apolo, M.D. Bladder Cancer Advocacy Network Jonathan Rosenberg MD

Great and highly practical breakout session on ‘Emerging and Next Generation Imaging for Bladder Cancer.’ Bladder Cancer Advocacy Network #BCANTT24 Manjiri Dighe Gopa Iyer Alvin Goh Memorial Sloan Kettering Cancer Center UW Radiology

We are looking for a talented clinical investigator focused on urothelial cancer. Join a great team focused on eradicating GU cancers! externaltalent-mskcc.icims.com/jobs/72285/fac…

Great opportunity to be mentored by a tremendous team of superb clinicians in one of the strongest environments for translational an clinical research!

Attention all junior investigators in #bladdercancer research! BCAN’s Career Development Award (CDA) is now open for submissions! Secure a 3-year, $250K grant to support your innovative research. Apply by October 11th, 2024. Learn more & retweet: bcan.org/bcan-research/…

Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions? Sometimes, but clinical judgement is more important than predefined criteria Andrea Apolo, M.D. Shilpa Gupta joaquim bellmunt Jonathan Rosenberg MD Michiel van der Heijden & Lisa Cordes gbr01.safelinks.protection.outlook.com/?url=https%3A%…

Congratulations Alan!

AMBASSADOR trial: After cystectomy, patients with muscle-invasive bladder cancer were randomly assigned to pembrolizumab or observation for 1 year. The pembrolizumab group had a median disease-free survival twice as long as the observation group. nej.md/4gh1b9D #ESMO24

The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24 Jonathan Rosenberg MD Matt Galsky

Truly an enormous national effort!

From @mattgalsky: Please consider opening the MODERN study (A032103). This study is being run through the Alliance and can be opened through the CTSU. The study employs central ctDNA testing to test escalation and de-escalation of adjuvant immunotherapy for MIBC. Thanks very much

We presented the 5-year OS update for pts who are cis-ineligible w/met UC treated in EV-103 cohort A/Dose Esc with EV/pembro: 41% of patients are alive at 5 years! (Historical data <5% in a similar pt population). If this holds up in EV302, it is truly a game changer! #ESMO2024